Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler

Key Points

• Piper Sandler lowered Perspective Therapeutics’ price target to $14 from $16 while maintaining an “overweight” rating, implying substantial upside from the stock’s $3.00 price.
• Analyst sentiment remains positive: eight analysts rate the stock a Buy, producing a consensus rating of “Buy” and an average price target of $12.38.
• Perspective Therapeutics beat quarterly EPS expectations, reporting a loss of $0.22 per share versus the expected $0.25 loss, though revenue was slightly below estimates and the company remains unprofitable.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) had its target price cut by equities researchers at Piper Sandler from $16.00 to $14.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's price target would indicate a potential upside of 366.67% from the company's current price.

Several other equities research analysts have also recently commented on CATX. BTIG Research reaffirmed a "buy" rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of "Buy" and a consensus target price of $12.38.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.00 on Tuesday. The business's 50-day moving average price is $3.10 and its 200-day moving average price is $3.93. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Analysts predict that Perspective Therapeutics will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the 4th quarter valued at $28,000. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the 4th quarter valued at $31,000. Abel Hall LLC bought a new position in Perspective Therapeutics during the 1st quarter valued at $49,000. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics during the 4th quarter valued at $35,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source